GUCY2C CAR-T cells

GUCY2C CAR-T cells are autologous chimeric antigen receptor (CAR) T cell therapies engineered to target guanylyl cyclase 2C (GUCY2C), a transmembrane protein highly expressed in colorectal cancer and other gastrointestinal malignancies. These therapies involve collecting a patient's own T cells and genetically modifying them to express a synthetic receptor that recognizes GUCY2C on tumor cells. Upon infusion back into the patient, these modified T cells selectively bind to and kill GUCY2C-expressing tumor cells through cytotoxic mechanisms. The design of the CAR construct often includes domains such as CD8α hinge/transmembrane regions for enhanced affinity and persistence, as well as costimulatory domains like CD28 and CD3ζ for robust activation[1][3][7]. Preclinical studies have demonstrated durable antitumor activity in mouse models of colorectal cancer metastases[3], while early-phase clinical trials have shown safety signals and preliminary efficacy in heavily pretreated patients with metastatic colorectal cancer[1][6]. The approach is also being explored for other gastrointestinal cancers including pancreatic adenocarcinoma[5].

Other names

anti-GUCY2C CAR-T cellsanti-GUCY-2C CAR-T cellsanti-GUCY 2C CAR-T cellsguanylyl cyclase 2C-targeted CAR-T cellsguanylate cyclase-C chimeric antigen receptor T-cell therapy